Literature DB >> 15194582

Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.

M C Wick1, S Lindblad, L Klareskog, R F Van Vollenhoven.   

Abstract

BACKGROUND: The relationship between inflammation and joint destruction in rheumatoid arthritis (RA) has not been unequivocally characterised. Joint destruction may result from the cumulative inflammatory burden over time, modified by an individual constant factor.
OBJECTIVE: To test the hypothesis that the relationship between radiological progression and inflammation can mathematically be expressed as: [equation: see text] where Re is a factor that varies from person to person.
METHODS: Clinical data and radiographs of 76 patients with early RA receiving different disease modifying antirheumatic drugs were analysed. Radiographs were quantified using the modified Larsen score and the "X-Ray RheumaCoach" software. The cumulative inflammatory burden was estimated by the time integrated 28 joint Disease Activity Score (DAS28), calculated as the area under the curve.
RESULTS: 76 patients with early RA who started treatment with methotrexate (n = 20), sulfasalazine (n = 37), or oral gold (n = 19) monotherapy were evaluated. The mean (SEM) DAS28 decreased from 4.6 (0.1) at baseline to 2.3 (0.1) after 2 years. The mean (SEM) DeltaLarsen score from baseline to year 2 was 10.3 (1.5). Correlation between cumulative inflammation and radiographic change was poor. In contrast, when calculating a person's factor Re in year 1 ( Re 1) and year 2 ( Re 2), a strong and significant correlation (r = 0.58, p<0.000001) was seen between Re 1 and Re 2.
CONCLUSIONS: Joint destruction is the result of the cumulative burden of inflammation over time, modified by an individual factor Re that remains relatively constant over the first 2 years of observation. The data support a mathematical model that expresses the interrelationship between inflammation and joint destruction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194582      PMCID: PMC1755049          DOI: 10.1136/ard.2003.015172

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers.

Authors:  Peter E Lipsky; David T Felson; Ravinder N Maini
Journal:  Arthritis Rheum       Date:  2002-10

2.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 3.  Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?

Authors:  Vibeke Strand; John T Sharp
Journal:  Arthritis Rheum       Date:  2003-01

4.  Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy.

Authors:  M Boers
Journal:  Arthritis Rheum       Date:  2001-11

5.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

Authors:  Robert B M Landewé; Maarten Boers; Arco C Verhoeven; Rene Westhovens; Mart A F J van de Laar; Harry M Markusse; J Christiaan van Denderen; Marie Louise Westedt; Andre J Peeters; Ben A C Dijkmans; Piet Jacobs; Annelies Boonen; Désirée M F M van der Heijde; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-02

6.  Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities.

Authors:  J T Sharp; M D Lidsky; L C Collins; J Moreland
Journal:  Arthritis Rheum       Date:  1971 Nov-Dec

Review 7.  The links between joint damage and disability in rheumatoid arthritis.

Authors:  D L Scott; K Pugner; K Kaarela; D V Doyle; A Woolf; J Holmes; K Hieke
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

8.  Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care.

Authors:  I E van der Horst-Bruinsma; I Speyer; H Visser; F C Breedveld; J M Hazes
Journal:  Br J Rheumatol       Date:  1998-10

9.  The "X-Ray RheumaCoach" software: a novel tool for enhancing the efficacy and accelerating radiological quantification in rheumatoid arthritis.

Authors:  M Wick; P Peloschek; K Bögl; W Graninger; J S Smolen; F Kainberger
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

10.  Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis.

Authors:  Philip G Conaghan; Philip O'Connor; Dennis McGonagle; Paul Astin; Richard J Wakefield; Wayne W Gibbon; Mark Quinn; Zunaid Karim; Michael J Green; Susanna Proudman; John Isaacs; Paul Emery
Journal:  Arthritis Rheum       Date:  2003-01
View more
  13 in total

1.  Dynamic exercises in patients with rheumatoid arthritis.

Authors:  A P Anandarajah; E M Schwarz
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

2.  Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.

Authors:  Yuri Kheifetz; Moran Elishmereni; Zvia Agur
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-09-18       Impact factor: 2.745

Review 3.  Treating very early rheumatoid arthritis.

Authors:  Karim Raza; Caitriona E Buckley; Mike Salmon; Christopher D Buckley
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

4.  The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases.

Authors:  Hakan Genc; Burcu Duyur Cakit; Baris Nacir; Meryem Saracoglu; Mahmut Kacar; Hatice Rana Erdem
Journal:  Clin Rheumatol       Date:  2006-11-04       Impact factor: 3.650

5.  Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.

Authors:  Fausto Salaffi; Marina Carotti; Alessandro Ciapetti; Stefania Gasparini; Emilio Filippucci; Walter Grassi
Journal:  BMC Musculoskelet Disord       Date:  2011-05-30       Impact factor: 2.362

6.  CD97 neutralisation increases resistance to collagen-induced arthritis in mice.

Authors:  Else N Kop; Janik Adriaansen; Tom J M Smeets; Margriet J Vervoordeldonk; René A W van Lier; Jörg Hamann; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Knee Arthritis Without Other Joint Symptoms in the Elderly With Seronegative Elderly Onset Rheumatoid Arthritis.

Authors:  Takatomo Mine; Koichiro Ihara; Hiroyuki Kawamura; Ryutaro Kuriyama; Ryo Date
Journal:  Open Orthop J       Date:  2016-12-30

8.  The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study.

Authors:  Sella A Provan; Kristin Angel; Sigrid Odegård; Petter Mowinckel; Dan Atar; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2008-06-23       Impact factor: 5.156

9.  Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.

Authors:  Maria L E Andersson; Björn Svensson; Ingemar F Petersson; Ingiäld Hafström; Kristina Albertsson; Kristina Forslind; Dick Heinegård; Tore Saxne
Journal:  BMC Musculoskelet Disord       Date:  2013-08-02       Impact factor: 2.362

10.  Time-averaged disease activity fits better joint destruction in rheumatoid arthritis.

Authors:  Hideaki Tsuji; Koichiro Yano; Moritoshi Furu; Noriyuki Yamakawa; Katsunori Ikari; Motomu Hashimoto; Hiromu Ito; Takao Fujii; Wataru Yamamoto; Koichiro Ohmura; Atsuo Taniguchi; Shigeki Momohara; Fumihiko Matsuda; Cornelia F Allaart; Hisashi Yamanaka; Tsuneyo Mimori; Chikashi Terao
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.